ADMA BIOLOGICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADMA BIOLOGICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $42.22M | Mar 25, 2021 |
| FY2020 | Dec 31, 2019 | $29.35M | Mar 25, 2021 |
| FY2018 | Dec 31, 2018 | $4.06M | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | $4.23M | Mar 13, 2019 |
| FY2018 | Jun 30, 2018 | $4.66M | Mar 13, 2019 |
| FY2018 | Mar 31, 2018 | $4.04M | Mar 13, 2019 |
| FY2018 | Dec 31, 2017 | $22.76M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $10.66M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $7.18M | Feb 24, 2017 |
| FY2015 | Dec 31, 2014 | $5.92M | Mar 23, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $510.17M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $426.45M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $258.22M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $154.08M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $80.94M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $42.22M | Mar 24, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $15.62M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $10.52M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $7.05M | Feb 24, 2017 |
| FY2015 | Dec 31, 2014 | $5.84M | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | $3.02M | Mar 9, 2015 |
| FY2013 | Dec 31, 2012 | $1.12M | Mar 28, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $292.77M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $219.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $88.94M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $35.27M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.17M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($19.07M) | Mar 24, 2022 |
| FY2018 | Dec 31, 2018 | ($25.21M) | Mar 13, 2019 |
| FY2018 | Dec 31, 2017 | ($6.40M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $4.30M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $2.87M | Feb 24, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.93M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $197.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($28.24M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($65.90M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | ($71.65M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($75.75M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($48.28M) | Mar 25, 2021 |
| FY2018 | Dec 31, 2018 | ($18.04M) | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | ($15.14M) | Mar 13, 2019 |
| FY2018 | Jun 30, 2018 | ($14.75M) | Mar 13, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $138.98M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $21.63M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($39.37M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | ($58.37M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($64.91M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($41.42M) | Mar 25, 2021 |
| FY2018 | Dec 31, 2018 | ($16.55M) | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | ($13.79M) | Mar 13, 2019 |
| FY2018 | Jun 30, 2018 | ($13.42M) | Mar 13, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.76M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.81M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $3.30M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $3.61M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $3.65M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $5.91M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.34M | Mar 25, 2021 |
| FY2024 | Apr 1, 2019 | $1.00M | Mar 18, 2025 |
| FY2018 | Dec 31, 2018 | $917.3K | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | $1.00M | Mar 13, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.58M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $74.12M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $59.02M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $52.46M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $42.90M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $35.05M | Mar 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.40M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $118.67M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $8.80M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($59.51M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | ($112.37M) | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | ($102.00M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($76.19M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($62.68M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($37.27M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($18.27M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.58M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.23M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $4.77M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $13.91M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $13.51M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $12.73M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.81M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.10M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.68M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $73.4K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $624.24M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $488.68M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $329.18M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $348.46M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $276.25M | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $207.67M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $127.09M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $88.88M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $108.02M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $23.69M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.92M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $139.66M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $193.98M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $196.49M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $135.08M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $119.42M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $100.90M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $69.11M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $67.69M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $28.14M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $477.32M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $349.02M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $135.21M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $151.97M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $141.17M | Mar 18, 2025 |
| FY2023 | Dec 31, 2020 | $88.25M | Feb 28, 2024 |
| FY2021 | Dec 31, 2019 | $26.19M | Mar 24, 2022 |
| FY2020 | Dec 31, 2018 | $19.77M | Mar 25, 2021 |
| FY2019 | Dec 31, 2017 | $40.33M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($4.46M) | Mar 13, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.53M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.53M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $3.53M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.53M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.53M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.53M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.53M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | $3.53M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.53M | Mar 13, 2019 |
| FY2018 | Dec 31, 2016 | $0 | Mar 13, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($161.65M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($308.58M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($506.26M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($478.02M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($412.11M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($340.47M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($264.72M) | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | ($216.44M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($150.69M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($106.93M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $87.63M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $103.15M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $51.35M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $86.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $51.09M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $55.92M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $26.75M | Mar 25, 2021 |
| FY2020 | Dec 31, 2018 | $26.75M | Mar 25, 2021 |
| FY2018 | Dec 31, 2017 | $43.11M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $9.91M | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.14M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $72.34M | Feb 25, 2026 |
| FY2019 | Dec 31, 2019 | $0 | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | $2.76M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.76M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $1.79M | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Mar 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 237.87M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 236.62M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | 226.06M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 221.82M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 195.81M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 104.90M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 59.32M | Mar 25, 2021 |
| FY2019 | Dec 31, 2018 | 46.35M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 36.73M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 12.89M | Mar 29, 2018 |